Menlo Park biotech AN2 Therapeutics files plans to go public
March 07, 2022 at 10:26 AM EST
The Menlo Park-based biotech is developing a therapy for non-tuberculous mycobacterial (NTM) lung disease, which typically attacks older people or those with a weakened immune system.
